Insulin resistance in obesity can be reliably identified from fasting plasma insulin

International Journal of Obesity

Volumn 39, Issue 12, 2015, Pages 1703-1709

  Ter Horst, K W ^a   Gilijamse, P W ^a   Koopman, K E ^a   De Weijer, B A ^a   Brands, M ^a   Kootte, R S ^a   Romijn, J A ^a   Ackermans, M T ^a   Nieuwdorp, M ^a   Soeters, M R ^a   Serlie, M J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLUCOSE; INSULIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ADULT; ARTICLE; BODY COMPOSITION; BODY FAT; BODY MASS; DIET RESTRICTION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; INSULIN BLOOD LEVEL; INSULIN CLEARANCE; INSULIN INFUSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; QUANTITATIVE INSULIN SENSITIVITY CHECK INDEX; REFERENCE VALUE; RESTING ENERGY EXPENDITURE; BLOOD; COMPARATIVE STUDY; EPIDEMIOLOGY; GLUCOSE CLAMP TECHNIQUE; LIVER; METABOLISM; MIDDLE AGED; NETHERLANDS; PREDICTIVE VALUE; SKELETAL MUSCLE; WHITE ADIPOSE TISSUE;

ADIPOSE TISSUE, WHITE; ADULT; BLOOD GLUCOSE; BODY MASS INDEX; FASTING; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; LIVER; MALE; MIDDLE AGED; MUSCLE, SKELETAL; NETHERLANDS; OBESITY; PREDICTIVE VALUE OF TESTS; REFERENCE VALUES;

EID: 84949625825     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2015.125     Document Type: Article

References (40)

1. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782-787
2. Accili D. Lilly lecture 2003: the struggle for mastery in insulin action: from triumvirate to republic. Diabetes 2004; 53: 1633-1642
3. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006; 444: 840-846
4. Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab 2008; 294: E15-E26
5. Samocha-Bonet D, Chisholm DJ, Tonks K, Campbell LV, Greenfield JR. Insulinsensitive obesity in humans-A favorable fat phenotype? Trends Endocrinol Metab 2012; 23: 116-124
6. Stern SE, Williams K, Ferrannini E, DeFronzo RA, Bogardus C, Stern MP. Identification of individuals with insulin resistance using routine clinical measurements. Diabetes 2005; 54: 333-339
7. Tam CS, Xie W, Johnson WD, Cefalu WT, Redman LM, Ravussin E. Defining insulin resistance from hyperinsulinemic-euglycemic clamps. Diabetes Care 2012; 35: 1605-1610
8. Gast KB, Tjeerdema N, Stijnen T, Smit JW, Dekkers OM. Insulin resistance and risk of incident cardiovascular events in adults without diabetes: meta-Analysis. PLoS One 2012; 7: e52036
9. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403
10. Langeveld M, Ghauharali KJ, Sauerwein HP, Ackermans MT, Groener JE, Hollak CE et al. Type I Gaucher disease, a glycosphingolipid storage disorder, is associated with insulin resistance. J Clin Endocrinol Metab 2008; 93: 845-851
11. Vrieze A, Van Nood E, Holleman F, Salojarvi J, Kootte RS, Bartelsman JF et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012; 143: 913-916
12. de Weijer BA, Aarts E, Janssen IM, Berends FJ, van de Laar A, Kaasjager K et al. Hepatic and peripheral insulin sensitivity do not improve 2 weeks after bariatric surgery. Obesity 2013; 21: 1143-1147
13. Koopman KE, Caan MW, Nederveen AJ, Pels A, Ackermans MT, Fliers E et al. Hypercaloric diets with increased meal frequency, but not meal size, increase intrahepatic triglycerides: a randomized controlled trial. Hepatology 2014; 60: 545-553
14. van Raalte DH, Brands M, van der Zijl NJ, Muskiet MH, Pouwels PJ, Ackermans MT et al. Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial. Diabetologia 2011; 54: 2103-2112
15. Brands M, Sauerwein HP, Ackermans MT, Kersten S, Serlie MJ. Omega-3 long-chain fatty acids strongly induce angiopoietin-like 4 in humans. J Lipid Res 2013; 54: 615-621
16. Vrieze A, Out C, Fuentes S, Jonker L, Reuling I, Kootte RS et al. Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity. J Hepatol 2014; 60: 824-831
17. van der Valk F, Hassing C, Visser M, Thakkar P, Mohanan A, Pathak K et al. The effect of a diiodothyronine mimetic on insulin sensitivity in male cardiometabolic patients: a double-blind randomized controlled trial. PLoS One 2014; 9: e86890
18. Ackermans MT, Pereira Arias AM, Bisschop PH, Endert E, Sauerwein HP, Romijn JA. The quantification of gluconeogenesis in healthy men by (2)H2O and [2-(13)C] glycerol yields different results: rates of gluconeogenesis in healthy men measured with (2)H2O are higher than those measured with [2-(13)C]glycerol. J Clin Endocrinol Metab 2001; 86: 2220-2226
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419
20. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85: 2402-2410
21. Steele R. Influences of glucose loading and of injected insulin on hepatic glucose output. Ann NY Acad Sci 1959; 82: 420-430
22. Finegood DT, Bergman RN, Vranic M. Estimation of endogenous glucose production during hyperinsulinemic-euglycemic glucose clamps. Comparison of unlabeled and labeled exogenous glucose infusates. Diabetes 1987; 36: 914-924
23. Solberg HE. The theory of reference values Part 5. Statistical treatment of collected reference values. Determination of reference limits. J Clin Chem Clin Biochem 1983; 21: 749-760
24. Clinical and Laboratory Standards Institute. Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory: Approved Guideline, 3rd edn. CLSI document EP28-A3c. Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2008
25. Karakelides H, Irving BA, Short KR, O'Brien P, Nair KS. Age, obesity, and sex effects on insulin sensitivity and skeletal muscle mitochondrial function. Diabetes 2010; 59: 89-97
26. Vistisen D, Colagiuri S, Borch-Johnsen K. Bimodal distribution of glucose is not universally useful for diagnosing diabetes. Diabetes Care 2009; 32: 397-403
27. Reaven GM. Banting lecture 1988: role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607
28. Amati F, Dube JJ, Coen PM, Stefanovic-Racic M, Toledo FG, Goodpaster BH. Physical inactivity and obesity underlie the insulin resistance of aging. Diabetes Care 2009; 32: 1547-1549
29. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2014; 37: S81-S90
30. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino Sr RB, Gibbons R et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: 2935-2959
31. Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G. Insulin resistance and hypersecretion in obesity. J Clin Invest 1997; 100: 1166-1173
32. Stefan N, Kantartzis K, Machann J, Schick F, Thamer C, Rittig K et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 2008; 168: 1609-1616
33. Ozturk ZA, Kadayifci A. Insulin sensitizers for the treatment of non-Alcoholic fatty liver disease. World J Hepatol 2014; 6: 199-206
34. Smith-Marsh D. Pharmacological strategies for preventing type 2 diabetes in patients with impaired glucose tolerance. Drugs Today (Barc) 2013; 49: 499-507
35. DeFronzo RA, Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care 2009; 32: S157-S163
36. Paquot N, Scheen AJ, Dirlewanger M, Lefebvre PJ, Tappy L. Hepatic insulin resistance in obese non-diabetic subjects and in type 2 diabetic patients. Obes Res 2002; 10: 129-134
37. Sherwin RS, Kramer KJ, Tobin JD, Insel PA, Liljenquist JE, Berman M et al. A model of the kinetics of insulin in man. J Clin Invest 1974; 53: 1481-1492
38. Doberne L, Greenfield MS, Schulz B, Reaven GM. Enhanced glucose utilization during prolonged glucose clamp studies. Diabetes 1981; 30: 829-835
39. Miller WG, Thienpont LM, Van Uytfanghe K, Clark PM, Lindstedt P, Nilsson G et al. Towards standardization of insulin immunoassays. Clin Chem 2009; 55: 1011-1018
40. Staten MA, Stern MP, Miller WG, Steffes MW, Campbell SE. Insulin assay standardization: leading to measures of insulin sensitivity and secretion for practical clinical care. Diabetes Care 2010; 33: 205-206